Bhatt Deepak L
Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Am J Cardiol. 2008 May 22;101(10A):4D-13D. doi: 10.1016/j.amjcard.2008.02.002.
There are 3 important factors that predispose patients to plaque rupture or recurrent events: plaque burden or multiple arterial plaques, the presence of persistent hyperreactive platelets, and ongoing vascular arterial inflammation. Successful therapeutic strategies focus on these predisposing factors, and the use of low-density lipoprotein-lowering medications (principally statins) and antiplatelet agents (principally aspirin) has had a major impact on the occurrence of cardiovascular outcomes and overall mortality over the last 2 decades. However, despite these interventions, a significant number of patients experience recurrent events or progression of disease. Novel compounds are being studied to determine, for example, whether an increase in high-density lipoprotein will provide additional risk reduction; to date, this has not proved to be sufficiently effective. Although early invasive management has been proved to be superior to medical therapy in patients with plaque rupture producing acute coronary syndromes, its superiority in patients with clinically stable obstructive disease has been questioned. Thus, the search for additional agents to improve the outcomes of patients with atherothrombotic disease continues. The importance of inflammation, a potentially critical element in the initiation, progression, and rupture of plaque, has become increasingly evident. In this supplement, the role of inflammation and its principal cause, oxidative stress, are analyzed as potential targets of pharmacologic therapy. The history of anti-inflammatory and antioxidant therapy in cardiovascular disease is critically examined. Finally, the whole process of contemporary drug discovery and development from lead rationale and identification through biologic screening and testing in animals and then humans is explored, using as an example the xanthophyll carotenoids, a class of potent antioxidants currently under investigation.
有3个重要因素使患者易发生斑块破裂或复发事件:斑块负荷或多个动脉斑块、持续存在的高反应性血小板以及持续的血管动脉炎症。成功的治疗策略聚焦于这些诱发因素,在过去20年中,使用降低低密度脂蛋白的药物(主要是他汀类药物)和抗血小板药物(主要是阿司匹林)对心血管结局的发生和总体死亡率产生了重大影响。然而,尽管采取了这些干预措施,仍有相当数量的患者经历复发事件或疾病进展。正在研究新型化合物,以确定例如高密度脂蛋白的增加是否会进一步降低风险;迄今为止,这尚未被证明足够有效。尽管早期侵入性治疗已被证明在患有斑块破裂导致急性冠状动脉综合征的患者中优于药物治疗,但其在临床稳定的阻塞性疾病患者中的优越性受到质疑。因此,寻找其他药物以改善动脉粥样硬化血栓形成疾病患者的结局的工作仍在继续。炎症作为斑块形成、进展和破裂中一个潜在的关键因素,其重要性日益明显。在本增刊中,炎症及其主要原因氧化应激的作用被分析为药物治疗的潜在靶点。对心血管疾病中抗炎和抗氧化治疗的历史进行了批判性审视。最后,以叶黄素类胡萝卜素为例,探索了当代药物发现和开发的全过程,从先导原理和鉴定到动物及随后人体的生物筛选和测试,叶黄素类胡萝卜素是一类目前正在研究的强效抗氧化剂。